{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:02:31Z","timestamp":1793332951939,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Beijing Biostar Tech, Ltd, Beijing, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0297-7","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T06:54:32Z","timestamp":1470898472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients"],"prefix":"10.1186","volume":"9","author":[{"given":"Pin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuguo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongguo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"issue":"11","key":"297_CR1","first-page":"2325","volume":"55","author":"DM Bollag","year":"1995","unstructured":"Bollag DM, McQueney PA, Zhu J. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325\u201333.","journal-title":"Cancer Res"},{"issue":"6","key":"297_CR2","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1073\/pnas.040546297","volume":"97","author":"P Giannakakou","year":"2000","unstructured":"Giannakakou P, Gussio R, Nogales E. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A. 2000;97(6):2904\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 5","key":"297_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/annonc\/mdm173","volume":"18","author":"P Fumoleau","year":"2007","unstructured":"Fumoleau P, Coudert B, Isambert N. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18 Suppl 5:9\u201315.","journal-title":"Ann Oncol"},{"issue":"33","key":"297_CR4","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","volume":"25","author":"ES Thomas","year":"2007","unstructured":"Thomas ES, Gomez HL, Li RK. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210\u20137.","journal-title":"J Clin Oncol"},{"key":"297_CR5","unstructured":"Bristol-Myers Squibb: Ixempra\u00ae Prescribing Information. 3\/2009 update.\u00a0 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022065lbl.pdf (date last Accessed: 1 June 2016)"},{"issue":"4","key":"297_CR6","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00280-011-1571-6","volume":"68","author":"P Zhang","year":"2011","unstructured":"Zhang P, Sun M, Qiu R. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68(4):971\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"297_CR7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CAD.0000000000000071","volume":"25","author":"CF Brogdon","year":"2014","unstructured":"Brogdon CF, Lee FY, Canetta RM. Development of other microtubule-stabilizer families: the epothilones and their derivatives. Anticancer Drugs. 2014;25(5):599\u2013609.","journal-title":"Anticancer Drugs"},{"issue":"19","key":"297_CR8","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161212800626238","volume":"18","author":"G Ferrandina","year":"2012","unstructured":"Ferrandina G, Mariani M, Andreoli M. Novel drugs targeting microtubules: the role of epothilones. Curr Pharm Des. 2012;18(19):2793\u2013803.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"297_CR9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.breast.2011.09.003","volume":"21","author":"J Jassem","year":"2012","unstructured":"Jassem J, Fein L, Karwal M. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast. 2012;21(1):89\u201394.","journal-title":"Breast"},{"issue":"23","key":"297_CR10","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","volume":"25","author":"EA Perez","year":"2007","unstructured":"Perez EA, Lerzo G, Pivot X. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407\u201314.","journal-title":"J Clin Oncol"},{"issue":"12","key":"297_CR11","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2005.10.024","volume":"23","author":"JA Low","year":"2005","unstructured":"Low JA, Wedam SB, Lee JJ. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23(12):2726\u201334.","journal-title":"J Clin Oncol"},{"issue":"20","key":"297_CR12","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","volume":"28","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Crocamo S, Costa VD, Ro J, Rubio G, Rondinon M, Manga GP, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28(20):3256\u201363.","journal-title":"J Clin Oncol"},{"issue":"23","key":"297_CR13","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","volume":"25","author":"E Thomas","year":"2007","unstructured":"Thomas E, Tabernero J, Fornier M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25(23):3399\u2013407.","journal-title":"J Clin Oncol"},{"issue":"6","key":"297_CR14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/med.20239","volume":"32","author":"S Nobili","year":"2012","unstructured":"Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev. 2012;32(6):1220\u201362.","journal-title":"Med Res Rev"},{"issue":"2","key":"297_CR15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.110.175604","volume":"337","author":"H Shen","year":"2011","unstructured":"Shen H, Lee FY, Gan J. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp\/MDR1\/ABCB1) but not breast cancer resistance protein (BCRP\/ABCG2). J Pharmacol Exp Ther. 2011;337(2):423\u201332.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"297_CR16","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-06-0242","volume":"5","author":"MNA Bijman","year":"2006","unstructured":"Bijman MNA, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VWM, Boven E. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 2006;5(9):2348\u201357.","journal-title":"Mol Cancer Ther"},{"key":"297_CR17","doi-asserted-by":"crossref","unstructured":"Kok JW, Klappe K, Hummel I. The role of the actin cytoskeleton and lipid rafts in the localization and function of the ABCC1 transporter. Adv Biol. 2014;3:1-11.","DOI":"10.1155\/2014\/105898"},{"issue":"1","key":"297_CR18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-014-0070-8","volume":"7","author":"A Smith","year":"2014","unstructured":"Smith A, Roda D, Yap T. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"297_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1756-8722-7-23","volume":"7","author":"CM Stellrecht","year":"2014","unstructured":"Stellrecht CM, Vangapandu HV, Le X-F, Mao W, Shentu S. ATP directed agent, 8-chloro-adenosine, induces AMP activated protein kinase activity, leading to autophagic cell death in breast cancer cells. J Hematol Oncol. 2014;7(1):23.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"297_CR20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/neuonc\/not305","volume":"16","author":"DM Peereboom","year":"2014","unstructured":"Peereboom DM, Murpgy C, Ahluwalia MS. Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro Oncol. 2014;16(4):579\u201383.","journal-title":"Neuro Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0297-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:29:30Z","timestamp":1498321770000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-016-0297-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0297-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,11]]},"article-number":"68"}}